Information Provided By: 
Fly News Breaks for July 8, 2015
BMRN
Jul 8, 2015 | 08:45 EDT
RBC Capital analyst Michael Yee raised his price target for BioMarin shares to $155 from $145 after hosting meetings with management. Yee left the meetings more positive on BioMarin's ability to win approval for its Duchenne Muscular Dystrophy drug and sees many catalysts for the stock by year-end. With FDA approval in DMD, Yee sees upside to $170-$180 for shares. In a takeout scenario, Yee sees upside potential of up to 100%. He keeps an Outperform rating on BioMarin. The orphan drug marker closed yesterday at $139.79.
News For BMRN From the Last 2 Days
There are no results for your query BMRN
